創薬市場：薬剤タイプ、技術、エンドユーザー、地域別、2026～2032年

創薬市場の評価-2026～2032年

創薬市場は、疾病の増加、技術の進歩、学界・産業・政府間の協力、個別化医療、有利な規制施策に後押しされ、2024年には評価額531億米ドルを突破します。

スクリーニング技術、計算モデリング、CRISPR/Cas9遺伝子編集のようなプラットフォームの進歩は、プロセスをより効率的でコスト効率の高いものにしています。個別化医療へのシフトと高齢化の進展も市場の成長に寄与しており、2026～2032年のCAGRは8.20%で、2032年には942億3,000万米ドルに達すると予想されています。

創薬市場定義/概要

創薬は、生物学、化学、薬理学、計算科学を含む学際的なプロセスで、新薬の同定と開発を行っています。標的の同定から始まり、標的の検証と高性能スクリーニング技術が続きます。化合物は有効性、副作用、薬剤動態学的特性について最適化されます。これらの化合物は、臨床検査に進む前に、in vitroやin vivoの実験を含む前臨床検査を受けています。臨床検査は極めて重要であり、ヒトを対象とした3段階で実施されます。規制当局がデータを審査し、医薬品の安全性と有効性を判断して承認を得る。新しい治療を患者に届けるためには、科学者、臨床医、規制当局、産業のパートナーの協力が不可欠です。

創薬市場を促進している要因は何か？

創薬は急速に発展しているセグメントであり、様々な要因の影響を受けています。高性能・スクリーニング、ゲノミクス、プロテオミクス、構造生物学などのセグメントにおける技術の進歩は、研究者が新たな対象を同定し、より効率的に医薬品を設計できるようにすることで、このプロセスに革命をもたらしました。

人工知能や機械学習などの計算機的手法は、薬剤と標的の相互作用を予測し、化合物の特性を最適化することで、プロセスを加速させています。学界、産業、政府機関の共同研究はイノベーションを促進し、創薬活動を加速させています。迅速な審査パスウェイや柔軟な承認基準といった規制の変化は、創薬研究への投資を促進します。ゲノミクスとバイオマーカーの同定によって促進される個別化医療は、治療効果を向上させ、副作用を軽減します。

薬剤の再利用は、コスト効率と時間効率の高い創薬アプローチを記載しています。ベンチャーキャピタル、政府機関、製薬会社からの投資はイノベーションを促進し、インフラ整備を支援します。新興感染症や慢性疾患といった世界の健康課題は、特定の治療領域への投資と研究の集中を促します。患者擁護団体や参加型研究モデルを含む患者中心のアプローチは、医薬品開発が患者のニーズや嗜好に合致することを保証します。大規模な生物医療データへのアクセスは、研究者が洞察を導き出し、新規創薬対象を特定し、治療仮説をより効果的に検証することを可能にします。

創薬市場の成長を妨げる障壁とは？

創薬は、様々な課題を伴う複雑なプロセスです。これには、対象の同定と検証、高性能スクリーニング、リードの最適化、前臨床検査、臨床検査のデザインと募集、規制上のハードル、コストと資金調達、特許保護と知的財産などが含まれます。厳密な科学的調査を通じて関連する分子標的を同定することは、創薬活動の成功にとって極めて重要です。

高性能スクリーニングには時間とコストがかかるため、より効率的なスクリーニング方法の開発が不可欠です。リード化合物の最適化は複雑な作業であり、広範なメディシナルケミストリーを必要とします。前臨床検査は、疾患モデルにおけるリード化合物の安全性と有効性を評価するものであるが、予測可能性やヒト生物学への適応性に関する課題に直面することがあります。

臨床検査のデザインと募集は、特に希少疾患や患者集団が限定される疾患の場合、課題となります。承認プロセスや資金確保などの規制上のハードルは、医薬品開発のタイムラインを遅らせる可能性があります。コストと資金調達も、特に成果が不確実な初期段階のプロジェクトにとっては大きな課題です。

知的財産権の保護は、技術革新のインセンティブを高め、投資を呼び込む上で極めて重要です。これらの課題に対処するためには、創薬プロセスを加速させ、安全で効果的な治療法を患者に提供するために、セグメントを超えた協力、革新的な技術、適応戦略が必要です。

目次

第1章 世界の創薬市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の創薬市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析
• 規制の枠組み

第5章 世界の創薬市場：薬剤タイプ別

• 概要
• 低分子医薬品
• 生物製剤

第6章 世界の創薬市場：技術別

• 概要
• 高性能スクリーニング
• ファーマコゲノミクス
• ナノテクノロジー

第7章 世界の創薬市場、エンドユーザー別

• 概要
• 製薬企業
• CRO（医薬品開発業務受託機関）

第8章 創薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の創薬市場の競合情勢

• 概要
• 企業市場ランキング
• ベンダー情勢
• 主要開発戦略

第10章 企業プロファイル

• Pfizer Inc.
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Agilent Technologies Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Abbott Laboratories Inc
• AstraZeneca PLC
• Shimadzu Corp

第11章 付録

• 関連調査

Drug Discovery Market Valuation - 2026-2032

The Drug Discovery Market is fueled by increasing disease prevalence, technological advancements, collaborations between academia, industry, and government, personalized medicine, and favorable regulatory policies, enabling the market surpass a valuation of USD 53.1 Billion evaluated in 2024.

Advances in screening techniques, computational modelling, and platforms like CRISPR/Cas9 gene editing have made the process more efficient and cost-effective. The shift towards personalized medicine and the growing aging population also contribute to the market's growth and is expected to reach USD 94.23 Billion by 2032, growing at a CAGR of 8.20% from 2026 to 2032.

Drug Discovery Market: Definition/ Overview

Drug discovery is a multidisciplinary process involving biology, chemistry, pharmacology, and computational science to identify and develop new medications. It starts with target identification, followed by target validation and high-throughput screening techniques. Compounds are optimized for efficacy, side effects, and pharmacokinetic properties. These compounds undergo preclinical studies, including in vitro and in vivo experiments, before advancing to clinical trials. Clinical trials are crucial, conducted in three phases involving human participants. Regulatory agencies review data to determine drug safety and effectiveness for approval. Collaboration between scientists, clinicians, regulatory authorities, and industry partners is essential for bringing new treatments to patients.

What Factors are Propelling the Drug Discovery Market?

Drug discovery is a rapidly evolving field that has been influenced by various factors. Technological advancements in areas like high-throughput screening, genomics, proteomics, and structural biology have revolutionized the process, allowing researchers to identify new targets and design drugs more efficiently.

Computational methods, such as artificial intelligence and machine learning, accelerate the process by predicting drug-target interactions and optimizing compound properties. Collaborative research between academia, industry, and government institutions fosters innovation and accelerates drug discovery efforts. Regulatory changes, such as expedited review pathways and flexible approval criteria, encourage investment in drug discovery research. Personalized medicine, facilitated by genomics and biomarker identification, improves treatment efficacy and reduces adverse effects.

Drug repurposing offers a cost-effective and time-efficient approach to drug discovery. Investment from venture capital firms, government agencies, and pharmaceutical company's fuels innovation and supports infrastructure development. Global health challenges, such as emerging infectious diseases and chronic conditions, drive investment and research focus in specific therapeutic areas. Patient-centric approaches, including patient advocacy groups and participatory research models, ensure that drug development aligns with patient needs and preferences. Access to large-scale biomedical data enables researchers to derive insights, identify novel drug targets, and validate therapeutic hypotheses more effectively.

What are the Barriers Impeding the Growth of the Drug Discovery Market?

Drug discovery is a complex process that involves various challenges. These include target identification and validation, high-throughput screening, lead optimization, preclinical studies, clinical trial design and recruitment, regulatory hurdles, cost and funding, and patent protection and intellectual property. Identifying relevant molecular targets through rigorous scientific investigation is crucial for the success of drug discovery efforts.

High-throughput screening is time-consuming and costly, and developing more efficient screening methods is essential. Lead optimization is a complex task that requires extensive medicinal chemistry efforts. Preclinical studies assess the safety and efficacy of lead compounds in disease models, but can face challenges related to predictability and translatability to human biology.

Clinical trial design and recruitment pose challenges, especially for rare diseases or conditions with limited patient populations. Regulatory hurdles, such as navigating the approval process and securing funding, can delay the drug development timeline. Cost and funding are also significant challenges, especially for early-stage projects with uncertain outcomes.

Protecting intellectual property rights is crucial for incentivizing innovation and attracting investment. Addressing these challenges requires collaboration across disciplines, innovative technologies, and adaptive strategies to accelerate the drug discovery process and deliver safe and effective treatments to patients.

Category-Wise Acumens

Which Drug Type has the Highest Market Share in the Drug Discovery Market?

Small molecule drugs are therapeutic agents with diverse chemical structures and mechanisms of action, with a significant market share in the drug discovery market. These drugs target chronic diseases like cardiovascular diseases, diabetes, and central nervous system disorders. Cardiovascular drugs, such as statins and antihypertensive agents, have a significant market share due to their high prevalence.

Diabetes drugs, like metformin and insulin analogues, command a substantial portion of the market due to the rising incidence of diabetes worldwide. Central nervous system disorders, like antidepressants, antipsychotics, and anxiolytics, address conditions like depression, schizophrenia, anxiety disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's. Oncology drugs also have a substantial market share due to the growing prevalence of cancer and the continuous development of targeted therapies and chemotherapy agents. Overall, small molecule drugs targeting chronic diseases like cardiovascular diseases, diabetes, and cancer have the highest market share in the drug discovery market.

How Pharmaceutical Companies are Expanding the Drug Discovery Market?

Pharmaceutical companies are expanding the drug discovery market through various strategies and innovations. They invest heavily in R&D to identify novel therapeutic targets and develop new drugs using advanced technologies like high-throughput screening, computational modeling, and artificial intelligence. They are also focusing on personalized medicine approaches, tailoring treatments to individual patients based on factors like genetic makeup and lifestyle.

Partnerships and collaborations with academic institutions, biotechnology startups, and other industry players help access new technologies and reduce the cost and risk associated with drug development. Pharmaceutical companies are exploring new therapeutic areas and indications, such as rare diseases, oncology, and neurodegenerative disorders, to address unmet medical needs and expand their market reach.

They are also expanding into emerging markets like Asia-Pacific, Latin America, and Africa, where there is growing demand for healthcare services and increased access to medicines. This strategy allows pharmaceutical companies to tap into new patient populations and drive market growth.

Country/Region-wise Acumens

Which Region Holds the Largest Market Share in Drug Discovery Market?

North America holds the largest market share in the drug discovery market due to its robust ecosystem of pharmaceutical and biotechnology companies, research institutions, academic centers, and government agencies. The region's leading pharmaceutical hubs, such as the San Francisco Bay Area, Boston-Cambridge, and San Diego, foster innovation and collaboration among industry players, academia, and research organizations.

The US Food and Drug Administration provides clear guidelines and pathways for drug development, ensuring rigorous standards for safety, efficacy, and quality assurance. North America's substantial investment in research and development fuels drug discovery initiatives, driving innovation and the development of novel therapeutics across various disease areas.

Additionally, the highly skilled workforce, including scientists, researchers, clinicians, and engineers, enables the region to tackle complex scientific challenges and pioneer groundbreaking approaches in drug development. The presence of world-class academic and research institutions also fosters collaboration and knowledge exchange, accelerating the pace of drug discovery and contributing to the region's leadership in the global pharmaceutical market.

What Factors are Driving the Rapid Expansion of the Asia-Pacific in Drug Discovery Market?

The Asia-Pacific region is experiencing a significant growth in the pharmaceutical industry, driven by rising healthcare expenditures, chronic diseases, and improved healthcare access. This has led to increased investment in drug discovery and development activities by both domestic and multinational pharmaceutical companies. The region is also witnessing a surge in biotechnology innovation and entrepreneurship, supported by government initiatives, venture capital funding, and collaborations with academia and research institutions. The region's rich biodiversity offers access to diverse biological resources, which researchers and pharmaceutical companies use for natural product screening, bio-prospecting, and drug discovery efforts.

Advanced research infrastructure, including state-of-the-art laboratories, research centers, and technology parks, is being built in countries like Japan, South Korea, Singapore, China, and India. Government support and incentives are also being implemented to attract investment and foster innovation in the biopharmaceutical sectors.

Rising collaboration and partnerships between pharmaceutical companies, research institutions, academia, and government agencies are driving innovation and knowledge exchange in drug discovery. The Asia-Pacific region's diverse population, including diverse ethnic groups and an increasing elderly population, provides access to large patient populations for clinical trials, biomarker discovery, and personalized medicine initiatives. Overall, the Asia-Pacific is a key player in global drug discovery efforts.

Competitive Landscape

The market is fiercely competitive, with established companies leveraging advanced technology, high-quality products, and strong brand image to drive revenue growth. They employ strategies like research, development, mergers, and technological innovations to expand their product portfolios.

Some of the prominent players operating in the drug discovery market are:

Fizer, Inc.

GlaxoSmithKline PLC

Merck & Co., Inc.

Agilent Technologies, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Bayer AG

Abbott Laboratories, Inc.

AstraZeneca PLC

Shimadzu Corp

Latest Developments

In October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.

In October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.

Drug Discovery Market, By Category

• Drug Type:
• Small-Molecule Drugs
• Biologic Drugs
• Technology:
• High Throughput Screening
• Pharmacogenomics
• End-Users:
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Region:
• North America
• Europe
• Asia Pacific
• Rest of the world

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE

• 5.1 Overview
• 5.2 Small Molecule Drugs
• 5.3 Biologic Drugs

6 GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 High Throughput Screening
• 6.3 Pharmacogenomics
• 6.4 Nanotechnology

7 GLOBAL DRUG DISCOVERY MARKET, BY END-USERS

• 7.1 Overview
• 7.2 Pharmaceutical Companies
• 7.3 Contract Research Organizations (CROs)

8 GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL DRUG DISCOVERY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market ranking
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Pfizer Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GlaxoSmithKline PLC
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merck & Co. Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agilent Technologies Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Eli Lilly and Company
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 F. Hoffmann-La Roche Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bayer AG
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Abbott Laboratories Inc
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 AstraZeneca PLC
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Shimadzu Corp
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 APPENDIX

• 11.1 Related Research